Pulmonary hypertension owing to lung disease and/or hypoxia

Pulmonary hypertension owing to lung disease and/or hypoxia (also known as Group 3 pulmonary hypertension in the WHO clinical classification) is a form of pulmonary hypertension that develops as a consequence of chronic lung diseases or conditions causing prolonged low oxygen levels (hypoxia). Common underlying causes include chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude, and developmental lung abnormalities. The condition is characterized by elevated blood pressure in the pulmonary arteries due to hypoxic vasoconstriction and structural remodeling of the pulmonary vasculature. The disease primarily affects the cardiovascular and respiratory systems. Chronic hypoxia triggers constriction and remodeling of the small pulmonary arteries, leading to increased pulmonary vascular resistance. Over time, the right ventricle of the heart must work harder to pump blood through the lungs, which can lead to right ventricular hypertrophy and eventually right heart failure (cor pulmonale). Key symptoms include progressive exertional dyspnea (shortness of breath during physical activity), fatigue, exercise intolerance, chest tightness, and in advanced stages, peripheral edema, syncope, and cyanosis. Symptoms of the underlying lung disease are also present. Treatment primarily focuses on managing the underlying lung disease and correcting hypoxia. Long-term supplemental oxygen therapy is a cornerstone of management for patients with documented hypoxemia, as it can reduce pulmonary artery pressure and slow disease progression. Optimization of the underlying pulmonary condition through bronchodilators, anti-inflammatory agents, or other disease-specific therapies is essential. Unlike pulmonary arterial hypertension (Group 1), the use of targeted pulmonary vasodilator therapies (such as phosphodiesterase-5 inhibitors or endothelin receptor antagonists) is generally not recommended in Group 3 pulmonary hypertension outside of clinical trials, as evidence of benefit is limited and these agents may worsen ventilation-perfusion mismatch. In severe, refractory cases, lung transplantation may be considered. Prognosis depends largely on the severity of the underlying lung disease and the degree of pulmonary hemodynamic impairment.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Pulmonary hypertension owing to lung disease and/or hypoxia